ASH 2009 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia-Reference-Cited by-同舟云学术

ASH 2009 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia

Published:2010-04 Issue:4 Volume:85 Page:283-286
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Fullmer Amber,Cortes Jorge,Kantarjian Hagop,Jabbour Elias

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.21662/fullpdf

Reference29 articles.

1. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

2. A Phase III randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (tyrosine kinase inhibitor optimization and selectivity) study;Cortes;Blood,2008

3. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

4. Randomized clinical trial for the optimization of imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV;Hehlmann;Haematologica,2009

5. Interferon alpha 2a (IFN) maintenance therapy after imatinib plus IFN induction therapy in chronic myeloid leukemia (CML) induces stable long-term molecular remissions and is associated with increased proteinase 3 (PR3) expression and the presence of PR1-Specific T-cells;Burchert;Blood,2009